Psilocybin-Research.comSearchable psilocybin and psilocin bibliometric database.
Email alerts

Application overview

Source-labeled psilocybin and psilocin literature for search, monitoring, export, and citation workflows.

How the research index is built

Eight research sources feed Psilocybin-Research.com PubMed, OpenAlex, Crossref, Europe PMC, ClinicalTrials.gov, PsyArXiv, bioRxiv, and medRxiv provide records that are reconciled into the central research index. psilocybin-research.com PubMed OpenAlex Crossref Europe PMC ClinicalTrials.gov PsyArXiv bioRxiv medRxiv
Source records are fetched, reconciled, and labeled before appearing in the live index. The original sources remain authoritative.

Research workflow

Search, filter, export, analyze, and monitor publications with source labels, publication status, citation links, alerts, API access, and a rights-safe SQLite download. Read about the methods and limitations. Explore the dataset and reuse guide or research trends by year.

Published

Study Protocol for “Exploring the safety and therapeutic potential of psilocybin in the treatment of anorexia nervosa in adolescents and young adults”

An abstract is available from the original source but is not redistributed by this tracker. Read the source record.

Open source BibTeX RIS

Bibliographic context

Journal
PLOS One
Date
2026-06-30
Source
Crossref
DOI
10.1371/journal.pone.0352246
PubMed
42378255

Authors

Sjöström DavidSchau Rybäck OleaClaesdotter Knutsson EmmaKajonius PetriJensen Sondén OskarCarlbring PerBjörkstrand JohannesMovahed Rad Pouya
Watch author

Derived topics and classifications

psilocybin Eating DisordersBrain ImagingAgingWellbeingPersonality ChangeClinical TrialRandomized Controlled TrialReview ArticleAdolescentsSafetyAdverse Events Randomized Controlled Trial

Citation graph

40 referenced DOIs found in stored source metadata. 1 indexed paper cite this DOI.

Open citation network

10.1016/s0140-6736(20)30059-310.1097/yco.000000000000073910.1001/archgenpsychiatry.2011.7410.1016/j.psychres.2015.09.00810.1016/j.amjmed.2015.06.03110.1186/s40337-024-01006-y10.1097/yco.000000000000045310.1016/j.jpsychires.2023.01.00210.1016/s2215-0366(15)00356-910.1016/s2215-0366(21)00038-910.1111/nyas.1531410.1016/j.neubiorev.2024.105820

Indexed papers citing this DOI

Study Protocol for “Exploring the safety and therapeutic potential of psilocybin in the treatment of anorexia nervosa in adolescents and young adults”2026-06-30

Related papers

Effect of MDMA-assisted therapy on mood and anxiety symptoms in advanced-stage cancer (EMMAC): study protocol for a double-blind, randomised controlled trial.Trials · 2024-05-21A Phase 3, Randomized, Double-Blind, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Psilocybin in Adults With Major Depressive Disorder (MDD)ClinicalTrials.gov · 2026-07-23A 24-Week, Multicentre, Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Clinical Trial to Evaluate Efficacy and Safety of Psilocybin-Assisted Psychotherapy in Adults With Alcohol Use Disorder (AUD)ClinicalTrials.gov · 2024-08-15Engaging Mood Brain Circuits with Psilocybin (EMBRACE): a study protocol for a randomized, placebo-controlled and delayed-start, neuroimaging trial in depression.Trials · 2024-07-03Psilocybin for alcohol use disorder: Rationale and design considerations for a randomized controlled trial.Contemporary clinical trials · 2022-12-01Comparative Policy Analysis of Psychedelic Therapy Regulation in Australia, Brazil, and the USAApplied Drug Research Clinical Trials and Regulatory Affairs · 2026-09-14A Phase III, Multicentre, Randomised, Double-blind, Controlled Study to Investigate the Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With Treatment-resistant DepressionClinicalTrials.gov · 2026-08-10A Phase III, Multicentre, Randomised, Double-blind, Placebo-controlled Study to Investigate the Efficacy, Safety, and Tolerability of COMP360 in Participants With Treatment-resistant DepressionClinicalTrials.gov · 2026-08-10